In the Australian pharmaceutical industry, there were 12 M&A deals announced in Q3 2024, worth a total value of $706.2m, according to GlobalData’s Deals Database. The $383m acquisition of IMBiologics by Nanjing Huadong Pharmaceutical was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q3 2024 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, M&A activity in Australia decreased by 25% in Q3 2024 compared with the previous quarter’s total of $943.5m and rose by 210% as compared to Q3 2023. Related deal volume increased by 20% in Q3 2024 versus the previous quarter and was 140% higher than in Q3 2023.
The top-ranked financial advisors supporting these M&A deals in Australia in 9M 2024 were Gresham House; Lazard; Moelis & Co with 1, 1, 1 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Australia in 9M 2024 were A&O Shearman; Bird & Bird; Bredin Prat & Associates with 2, 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2024 – Strategic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.